- In a report published Tuesday, Evercore ISI analyst Mark Schoenebaum enumerated the upcoming catalysts for Biogen Idec Inc (NASDAQ: BIIB). These include:
Quarterly calls: Tecfidera sales number
March 2015 - ADPD Conference: BIIB-037 Ph 1b mild / prodromal alzheimer's detailed data
April 2015 (AAN Conference): Detailed LINGO (Optic Neuritis) Phase 2 data
1H15: Alprolix Kids B-Long Phase 3 data readout
2H15: Tysabri Phase 3 SPMS readout
2H15: Neublastin - Ph 2 Painful Lumbar Radiculopathy readout
2015: Tysabri Phase 2 acute ischemic stroke data
2015: Gazyva DLBCL Phase 3 data
2015: STX-100 - Ph2a IPF (n=32)
2016: Anti-LINGO - Ph 2 MS trial (SYNERGY)
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Although interim results would be declared in 2H15, they could remain blinded, not offering any data, the analyst added.